Why Compare Wegovy vs Mounjaro Doses Privately in the UK?
Private Prescription Advantages: Wegovy Dose vs Mounjaro Dose Access
When comparing Wegovy dose vs Mounjaro dose options, the private prescription route eliminates the barriers typical of NHS weight management pathways. Rather than waiting 6+ months for specialist referral and strict BMI criteria assessment, EverydayMeds provides immediate access to both semaglutide and tirzepatide treatments through our GPhC-registered service (#9012878). The NHS route requires GP referral to specialist weight management services, often with limited availability and postcode lottery access variations.
Private prescription allows you to compare Wegovy dose vs Mounjaro dose schedules with personalised prescriber guidance, receiving the same genuine Novo Nordisk Wegovy or Eli Lilly Mounjaro supplied to NHS patients. Your clinical assessment considers individual factors like previous medication response, lifestyle preferences, and storage requirements — particularly relevant when weighing Wegovy's 6-week room temperature advantage against Mounjaro's 21-day limit for travel or fridge-free periods.
Wegovy vs Mounjaro Dose Pricing: Complete UK Cost Breakdown
Understanding the financial commitment when comparing Wegovy dose vs Mounjaro dose schedules helps inform your treatment choice. Wegovy pricing starts at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg) to £209.99 for the 2.4mg maintenance dose. New customers apply code FIRST40 at checkout, while returning customers use DOSE25 for these final prices.
Our bundle options provide convenience for the complete Wegovy dose vs Mounjaro dose comparison journey. The Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, covering your first 12 weeks, while the Ultimate Stability Trio provides three months of 2.4mg maintenance for £649.99. Mounjaro follows a different dosing pattern with 2.5mg, 5mg, 10mg, and 15mg options, allowing direct consultation with our prescribers about which Wegovy dose vs Mounjaro dose progression suits your clinical profile.
Clinical Evidence: Wegovy Dose vs Mounjaro Dose Trial Results
In clinical trials, patients taking Wegovy alongside diet and exercise experienced approximately 15% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The standardised Wegovy dose escalation from 0.25mg to 2.4mg over 16 weeks showed sustained results, with STEP 5 demonstrating clinically studied weight loss maintained at 2 years. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events among patients following the established Wegovy dose protocol.
When evaluating Wegovy dose vs Mounjaro dose clinical performance, it's important to note that direct head-to-head trials remain limited, with different trial designs and patient populations making percentage comparisons inappropriate. Mounjaro's dual GIP and GLP-1 receptor mechanism operates differently from Wegovy's GLP-1-only approach, potentially influencing individual response patterns that your prescriber can discuss during assessment.
How Wegovy Works: GLP-1 Mechanism in Dose Comparison Context
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormone that signals satiety and reduces appetite. Each weekly injection, from the initial 0.25mg through to 2.4mg maintenance, works on brain appetite centres to promote feelings of fullness after smaller meals and may reduce food cravings between eating occasions. This mechanism explains why the Wegovy dose vs Mounjaro dose comparison often centres on individual response to GLP-1 stimulation versus Mounjaro's additional GIP receptor activity. The prescription-only medicine requires administration alongside a reduced-calorie diet and increased physical activity to achieve optimal weight management outcomes. Understanding this mechanism helps inform your Wegovy dose vs Mounjaro dose decision based on how your body responds to appetite regulation strategies.
Streamlined Ordering: Wegovy Dose vs Mounjaro Dose Assessment Process
EverydayMeds' clinical assessment process simplifies comparing Wegovy dose vs Mounjaro dose options without lengthy NHS waiting periods. Our 3-minute online questionnaire captures your medical history, current medications, weight management goals, and any previous GLP-1 or dual-agonist experience. Prescriber review typically takes 3 working days (express 24-hour service available), during which your clinical profile is matched against both Wegovy and Mounjaro suitability criteria. Once approved, next-day delivery ensures your chosen prescription-only medicine arrives via temperature-controlled cold-chain logistics. The entire process from initial Wegovy dose vs Mounjaro dose enquiry to receiving your medication typically completes within one week, compared to 6+ months through traditional NHS referral pathways.
Storage and Practical Considerations: Wegovy vs Mounjaro Dose Management
Practical storage differences significantly impact the Wegovy dose vs Mounjaro dose decision for many patients. Wegovy pens maintain potency for 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit, making Wegovy advantageous for frequent travel or workplace storage. Both medications require refrigeration at 2-8°C before first use, arriving in EverydayMeds' specialised cold-chain packaging. The FlexTouch pen design for Wegovy offers intuitive dose selection through the escalation schedule, while Mounjaro's KwikPen provides similar user-friendly injection experience. Each medication follows strict dose escalation protocols — Wegovy cannot skip from 0.25mg directly to 1mg, just as Mounjaro requires gradual titration through 2.5mg, 5mg, 10mg progression to minimise gastrointestinal side effects common to both GLP-1 and dual-agonist therapies.
Private vs NHS Route: Why Wegovy Dose vs Mounjaro Dose Comparison Matters
The private prescription advantage becomes particularly relevant when comparing Wegovy dose vs Mounjaro dose accessibility through different healthcare pathways. NHS NICE guidance (TA875) recommends Wegovy specifically within specialist weight management services, often creating bottlenecks where patients cannot access either option despite meeting clinical criteria. Private prescription eliminates this gatekeeping, allowing direct comparison of how your body responds to Wegovy's dose escalation versus Mounjaro's different titration schedule.
Additionally, private prescription provides flexibility to switch between treatments if initial response proves suboptimal, something rarely possible within NHS pathways due to formulary restrictions and referral requirements. This adaptability proves crucial given that individual response to Wegovy dose vs Mounjaro dose regimens varies significantly, with some patients responding better to pure GLP-1 stimulation while others benefit from Mounjaro's dual-hormone approach.
Making Your Choice: Wegovy Dose vs Mounjaro Dose Prescriber Guidance
Your final Wegovy dose vs Mounjaro dose decision benefits from personalised prescriber consultation considering factors beyond basic BMI criteria. Previous experience with diabetes medications, gastrointestinal sensitivity, injection frequency preferences, and storage convenience all influence treatment suitability. EverydayMeds prescribers can discuss how Wegovy's established dose progression compares to Mounjaro's newer dual-agonist approach for your specific circumstances. Both medications are available through our service, ensuring your choice remains clinical rather than limited by supply constraints. Use discount codes FIRST40 (new customers) or DOSE25 (returning customers) at checkout, with both treatments available for next-day delivery from our GPhC-registered pharmacy. Start your assessment today to determine which option aligns best with your weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
